Nanoparticle Breakthrough: Cerium Oxide Shields the Liver from Sevoflurane-Induced Damage, study finds

The Double-Edged Sword of Sevoflurane

Sevoflurane is a popular inhalational anesthetic, praised for its safety and efficacy in surgeries. However, isolated reports have raised concerns about its potential to cause liver damage—an effect tied to oxidative stress and the generation of harmful metabolites. With the rise of nanomedicine, scientists are turning to innovative agents like cerium oxide nanoparticles (CeO₂), known for their powerful antioxidant properties, to find solutions for drug-induced organ injury.

The Study: Testing Cerium Oxide’s Hepatic Defense

Recently published pioneering experimental study, researchers at Ankara Bilkent City Hospital explored whether cerium oxide could protect against sevoflurane-induced liver injury. They divided 24 Wistar rats into four groups:

1. Control: No intervention.

2. Sevoflurane (S): Exposed to sevoflurane.

3. Cerium Oxide (CeO₂): Received cerium oxide.

4. Sevoflurane + Cerium Oxide (S+CeO₂): Received cerium oxide before sevoflurane exposure.

Researchers measured liver enzymes (ALT, AST, LDH) and examined liver tissues for signs of cellular damage.

Key Findings: Cerium Oxide Reduces Liver Damage

• Histopathology: Rats exposed to sevoflurane alone showed significant liver cell swelling (hydropic degeneration) and neutrophil infiltration—classic signs of liver stress and injury. These effects were markedly reduced in rats that received cerium oxide, either alone or combined with sevoflurane.

• Biochemistry: Sevoflurane exposure raised AST and LDH levels, indicating liver distress. Notably, LDH levels were significantly lower in the S+CeO₂ group than in the sevoflurane-only group, suggesting cerium oxide’s protective effect.

• No Added Toxicity: Cerium oxide alone did not cause liver damage, supporting its safety at the tested dose.

A Step Toward Hepatoprotective Nanomedicine

The study provides the first experimental evidence that cerium oxide nanoparticles can mitigate sevoflurane-induced liver injury. The antioxidant ability of CeO₂ appears to offset the oxidative stress and cellular infiltration triggered by sevoflurane. While changes in some liver enzymes (especially AST) did not reach statistical significance, the improvements in tissue health are promising.

Researchers caution that further studies are needed, especially with different doses, prolonged exposures, and in subjects with pre-existing liver conditions, to optimize safety and efficacy for clinical use.

Key Takeaways:

• Sevoflurane can cause oxidative liver damage, even with short-term exposure.

• Cerium oxide nanoparticles significantly reduce liver tissue injury and some enzyme markers.

• This is the first study to show cerium oxide’s protective effects on sevoflurane-induced hepatic injury.

• Further research is needed to validate these findings before clinical application.

Citation:

Erbay F, Öztürk L, Kıran MM, Gök G, Arslan M. The effect of cerium oxide on liver in sevoflurane-administered rats: an experimental study. BMC Anesthesiology. 2025;25:251. https://doi.org/10.1186/s12871-025-03126-7